During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Courtney DiNardo, MD Anderson Cancer Center, Houston, US, about the Viale-A trial. We asked, Should azacitidine + venetoclax become standard of care for elderly patients with newly diagnosed AML?
In the Viale-A trial, patients treated with azacitidine + venetoclax demonstrated significantly improved survival outcomes vs those who received azacitidine alone. Courtney DiNardo suggests that azacitidine + venetoclax is a clinically effective strategy that should be considered as standard of care for elderly patients with newly diagnosed AML.